

97.7% of Rx); Other general merchandise, 31.0%. Stores average 21482 Walgreens Boots Alliance, the newest 8.5% 10.0%

13089

5806

17013 18547 Current Liab. ANNUAL RATES Past Est'd '15-'17 Past to '21-'23 10 Yrs. of change (per sh) 5 Yrs. 8.5% 10.0% 7.0% 11.0% Sales "Cash Flow" 11.0% 7.5% 8.0% Earnings Dividends 10.0% 13.0% 18.0% 10.5% 13.0% Book Value 10.0%

11000 323

5690

12594 251 5802

Accts Payable Debt Due Other

20011 101070 101070 01070					
Fiscal Year Ends	QUA Nov.30	RTERLY S Feb.28	ALES (\$ m May 31		Full Fiscal Year
2015	19554	26573	28795	28522	103444
2016	29033	30184	29498	28636	117351
2017	28501	29446	30118	30149	118214
2018	30740	33021	34334	33905	132000
2019	32650	34750	36250	36100	139750
Fiscal	EARNINGS PER SHARE ABFull				
Year Ends	Nov.30	Feb.28	May 31	Aug.31	Fiscal Year
2015	.81	1.18	1.02	.88	3.88
2016	1.03	1.31	1.18	1.07	4.59
2017	1.10	1.36	1.33	1.31	5.10
2018	1.28	1.73	1.53	1.51	6.05
2019	1.40	1.85	1.60	1.65	6.50
Cal-	Cal- QUARTERLY DIVIDENDS PAID C ■				
endar	Mar.31	Jun.30	Sep.30	Dec.31	Year
2014	.315	.315	.3375	.3375	1.26
2015	.3375	.3375	.360	.360	1.40
2016	.360	.360	.375	.375	1.46
2017	.375	.375	.400	.400	1.53
2018	.40	.40	.44		

member of the Dow-30, posted solid third-quarter financial results. (Fiscal 2018 ended August 31st.) The top line increased a slightly better than expected 14%, to \$34.3 billion, thanks mostly to strength in the pharmacy business. Indeed, pharmacy sales were up 19%, year over year. Same-store sales were flat, but the addition of Rite Aid stores drove the overall improvement. Meantime, earnings

across the globe, including 8,100 locations in 50 states and Puerto

Rico. In 2017, pharmacy contributed 69.0% of sales (3rd party,

clocked in at a better-than-anticipated \$1.53 a share, 15% higher than the yearearlier tally and a nickel ahead of our call. Share repurchases and a lower tax rate, thanks to the Tax Cuts and Jobs Act, were further boons.

We think that the company is being cautious with its guidance. Management tweaked its full-year fiscal 2018 share-earnings estimate, tacking just a nickel onto the bottom of its range, now \$5.90-\$6.05. The midpoint assumes a 17% gain for all of fiscal 2018 and a 10% advance for the fourth quarter. However, we are optimistic based on the company's performance, strong first-half likelihood of further below-the-operatingRock, Inc., 5.5% (12/17 Proxy). CEO; Stefano Pessina. Chairman: James A. Skinner. Inc.: IL. Address: 108 Wilmot Road, Deerfield, IL 60015. Telephone: 847-914-2500. Internet: www.walgreens.com line tailwinds, and contributions from the

Rite Aid additions. It should be noted that the board of directors has authorized \$10 billion in share repurchases. Adding it all up, we are modeling for \$1.51 in share earnings in the August quarter and \$6.05 for the full year. Our fiscal 2019 share-net forecast remains intact at \$6.50.

These shares have trended upwards in price since our June review, but are still trading a long ways off their year-to-date peak and even further below their 2016 all-time high. Investor sentiment continues to be dampened by an increasingly competitive market environment and uncertainty about the future of the United States' healthcare system. The stock has slipped two notches for Timeliness and is now pegged to mirror the market in the coming six to 12 months. However, we still like Walgreens' longer-term prospects, given the company's market position, diversified business model, financial flexibility, and management's willingness to make moves such as its recent pairing with Humana to open seniorfocused care centers in existing locations. Andre J. Costanza September 14, 2018

(A) Fiscal year ends August 31st.
(B) Based on diluted shares. Excludes nonrecurring gains (losses): '02, 1¢; '03, 2¢; '04, 1¢; '10, (4¢); '11, 30¢; '12, (11¢); '13, (5¢); '14,

(90¢); '15, 12¢; '16, (77¢); '17, (\$1.32); '18, (7¢). May not add due to rounding. Next earnings report due late Oct. **(C)** Dividends historically paid in March, June, Sept., and Dec.

Direct stock purchase plan avail. (includes dividend reinvest.).

Company's Financial Strength Stock's Price Stability A+ 75 Price Growth Persistence 60 **Earnings Predictability** 85